Gilead-Teva Patent Deal Cost Drug Buyers Over $2B, Jury Told
A retired Harvard Medical School health economics professor testified Tuesday in a California federal antitrust trial over claims that Gilead and Teva struck an illegal "pay for delay" patent deal over...To view the full article, register now.
Already a subscriber? Click here to view full article